Email this article Co-renitek treatment of patients withmoderate and severe forms of hypertensive disease
- Authors: Chazova IE1, Rat ova LG1, Dmhriev VV1, Khanbalaeva MN1, Kolkina TI1
-
Affiliations:
- Российский кардиологический научно-производственный комплекс Минздрава РФ, Москва
- Issue: Vol 78, No 8 (2003)
- Pages: 21-26
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33350
- ID: 33350
Cite item
Full Text
Abstract
Aim. To evaluate efficacy and tolerance of a compound drug co-renitec combining an ACE inhibitor
enalapril maleate and diuretic hydrochlorothiazide co-renitec taken for 16 weeks in essential hypertension (EH).
Material and methods. 28 patients with EH (16 males and 12 females aged 47-74 years) of mean
duration 13.1+1.6 years. Blood pressure (Bp) was monitored for 24 hours with the device SL 90207
(SpaceLabs Medical, USA). Microalbuminuria (MAD) was estimated with the use of immunoturbodimetric test.
Results. By 24-hour monitoring, co-renitec reduced day BP by 14.9/8.9 ± 3/2 mm Hg, nocturnal BP
lowered by 18.6/11.4 ± 3/2 mmHg, pulse pressure also fell. Coefficient T/P was 53.5% for systolic BP
(SBP) and 59.6% for diastolic BP (DBP). The target SBP was reached in 77% patients, target DBP -in 69%.
Co-renitec significantly decreased MAU, albumines excretion normalized in 46% patients.
Conclusion. Co-renitec lowers both day and nocturnal blood pressure, improves 24-h rhythm of BP,
has a positive effect on the kidneys. This allows its recommendation as a first-line drug in patients with
moderate and severe EH.
enalapril maleate and diuretic hydrochlorothiazide co-renitec taken for 16 weeks in essential hypertension (EH).
Material and methods. 28 patients with EH (16 males and 12 females aged 47-74 years) of mean
duration 13.1+1.6 years. Blood pressure (Bp) was monitored for 24 hours with the device SL 90207
(SpaceLabs Medical, USA). Microalbuminuria (MAD) was estimated with the use of immunoturbodimetric test.
Results. By 24-hour monitoring, co-renitec reduced day BP by 14.9/8.9 ± 3/2 mm Hg, nocturnal BP
lowered by 18.6/11.4 ± 3/2 mmHg, pulse pressure also fell. Coefficient T/P was 53.5% for systolic BP
(SBP) and 59.6% for diastolic BP (DBP). The target SBP was reached in 77% patients, target DBP -in 69%.
Co-renitec significantly decreased MAU, albumines excretion normalized in 46% patients.
Conclusion. Co-renitec lowers both day and nocturnal blood pressure, improves 24-h rhythm of BP,
has a positive effect on the kidneys. This allows its recommendation as a first-line drug in patients with
moderate and severe EH.
About the authors
I E Chazova
Российский кардиологический научно-производственный комплекс Минздрава РФ, МоскваРоссийский кардиологический научно-производственный комплекс Минздрава РФ, Москва
L G Rat ova
Российский кардиологический научно-производственный комплекс Минздрава РФ, МоскваРоссийский кардиологический научно-производственный комплекс Минздрава РФ, Москва
V V Dmhriev
Российский кардиологический научно-производственный комплекс Минздрава РФ, МоскваРоссийский кардиологический научно-производственный комплекс Минздрава РФ, Москва
M N Khanbalaeva
Российский кардиологический научно-производственный комплекс Минздрава РФ, МоскваРоссийский кардиологический научно-производственный комплекс Минздрава РФ, Москва
T I Kolkina
Российский кардиологический научно-производственный комплекс Минздрава РФ, МоскваРоссийский кардиологический научно-производственный комплекс Минздрава РФ, Москва
References
- Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC V 1). Arch. Intern. Med. 1997; 157: 2413-2465.
- Chockalingham A., Fodoz J. G. Treatment of raised blood pressure in the population. The Canadian experience. Am. J. Hypertens. 1998; 11: 747-749.
- Colhoun H. M, Dong W., Poulter N. R. Blood pressure screening, management and control in England; results from the health survey for England. 1994. J. Hypertens. 1998; 17: 151 - 183.
- Преображенский Д. В., Сидоренко Б. А. Лечение артериальной гипертензии. М.: Практ. врач; 1999.
- Тареева И. Е., Мухин Н. А., Потапова А. В. Тубулоинтерстициальные поражения почек в нефрологической клинике. Клин. мед. 1994; 1: 64-69.
- The HOT Study Group. The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure 1993; 2: 62-68.
- Чазова И. Е. Комбинированная терапия артериальной гипертензии. Consilium Medicum. 2001; 2: Прил. Артер. гипертенз. 22-26.
- Parati G., Pomidossi G., Albini F. et al. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J. Hypertens. 1987; 5: 93-98.
- Кобалава Ж. Д., Котовская Ю. В. Мониторирование артериального давления: методические аспекты и клиническое значение/ Под ред. В. С. Моисеева. М.: Сервье, 1999. 1999. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J. Hypertens. 1999; 17: 151-183.
- Verdecchia P., Schillaci G., Borgioni C. et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983-988.
- Ольбинская Л. И., Мартынов А. И., Хапаев Б. А. Мониторирование АД в кардиологии. М.: Русский врач; 1998.
- Суточное мониторирование артериального давления: (Методические вопросы) / Рогоза А. Н., Никольский В. П.,Ощепкова Е. В. и др. Под ред. Г. Г. Арабидзе, О. Ю. Атькова. М.: 1997.
- Ольбинская Л. И., Хапаев Б. А. Оценка стабильности эффекта и безопасности антигипертензивной терапии. Клин. фармакол. и тер. 1998; 3: 25-28.
- Madhavan S., Ooi W. L., Alderman M. N. Relation of pulse pressure and reduction to the incidence of myocardial infarction. Hypertension. 1994; 23: 395-401.
- Benetos A., Safar M., Rudnichi A. et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Ibid. 1997; 30: 1410-1415.
- Manchia G., Gamba P. L., Omboni S. et al. Ambulatory blood pressure monitoring. J. Hypertens. 1996; 14(2): 61-68.
- Горбунов В. М., Метелица В. И., Дуда С. Г. и др. Степень ночного снижения артериального давления: воспроизводимость и эффект трех р-адреноблокаторов. Кардиология 1999; 4: 21-25.
- Зелвеян П. А., Ощепкова Е. В., Буниатян М. С. и др. Суточный ритм АД и состояние органов-мишеней у больных с мягкой и умеренной формами ГБ. Тер. арх. 2001; 2: 33-38.
- Neki N. S., Arora P. A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension. J. Indian Med. Assoc. 2001; 99(11): 640-641.
- Zannad F., Gosse P., Bernard-Fernier M. F. et al. Antihypertensive efficacy and tolerability of diltiazem and enalapril, alone on in combination. DESG. Diltiazem Enalapril. Presse Med. 1994; 23(29): 1335-1338.
- Mayaudon H., Chanudet X., Janin G. et al. Comparison of the efficacy of enalapril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in mild-to-moderate arterial hypertension by ambulatory measurement of blood pressure. Ann. Cardiol. Angeiol. (Paris) 1995; 44(5): 235-241.
- Литвин А. Ю. Микроальбуминурия: методы определения и клиническое значение. Consilium Medicum 2001; 2(Прил. Артер. гипертенз.): 14-16.
- Bigazzi R., Bianchi S., Baldari D. et al. Long term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am. J. Hypertens. 1993. 6(2): 108-113.
- Bianchi S., Bigazzi R., Baldari G. et al. Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. Am. J. Med. 1992; 93(5): 525-528
Supplementary files
